摘要
目的比较国产和进口阿德福韦酯分别联合α1胸腺肽治疗慢性乙型肝炎(HBV)患者的疗效。方法 100例HBV患者分为观察组及对照组。观察组:丁贺联合胸腺肽α1治疗患者。对照组:贺维力联合胸腺肽α1治疗患者。结果两组疗效比较差异不显著(P>0.05)。两组阴转率差异不显著(P>0.05)。观察组治疗后T-BiL、ALT、Child-Pugh分级评分与对照组分别比较,差异不显著(P>0.05)。两组不良反应比较无显著性差异(P>0.05)。结论国产ADV联合α1胸腺肽治疗了HBV患者疗效可靠,也相对安全,实惠,值得在临床进一步推广。
Objective Evaluation efficacy of domestic and imports adefovir dipivoxil respectively with α1 thymosin treatment of chronic hepatitis ]3. Methods 100 cases of HBV patients, divided into two groups and the control group. Observer Group ： Ding He, patients treated with thymosin α1. Control group ： Geoffrey force, thymosin α1 treatment of patients. Results Two groups, efficacy, the difference was not significant （ P 〉 0.05 ）. Two groups, negative rate, the difference was not significant （P 〉0.05 ）. Observation group, after treatment, T- BiL, ALT, Child- Pugh classification score, and the control group, the difference was not significant （ P 〉 0.05 ）. Two groups of adverse reactions, no significant difference （ P 〉 0.05）. Conelution Thyraosin α1 domestic ADV joint, effective and reliable treatment of HBV patients, but also relatively safe, affordable, valuable in the further.
出处
《中国医学创新》
CAS
2010年第29期43-44,共2页
Medical Innovation of China
